Clinical Trials on Metastatic Differentiated Thyroid Cancer in Belgium

Total 338 results

Genzyme, a Sanofi Company

Completed

CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice (CaprelsaReg)

Metastatic Medullary Thyroid Cancer

Belgium
Exelixis
Ipsen

Active, not recruiting

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Differentiated Thyroid Cancer

Hong Kong, Italy, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Croatia, Czechia, France, Germany, Hungary, Israel, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Spain, Taiwan, ... and more
European Organisation for Research and Treatment...

Completed

Nintedanib(BIBF1120) in Thyroid Cancer

Differentiated Thyroid Cancer (DTC) | Medullary Thyroid Cancer (MTC)

France, Belgium, Denmark, Italy, Netherlands, Germany, Poland, Spain, United Kingdom
Jules Bordet Institute

Completed

Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers (MOMENTUM1)

Metastatic Colorectal Cancers | Metastatic Gastric Cancers | Metastatic Oesophageal Cancers | Metastatic Pancreatic Cancers | Metastatic Biliary Cancers | Metastatic Breast Cancers

Belgium
Genzyme, a Sanofi Company
Worldwide Clinical Trials

Completed

Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer (Caprelsa104)

Symptomatic, Aggressive, Sporadic, Unresectable, Locally | Advanced/Metastatic Medullary Thyroid Cancer (MTC)

Belgium, Italy, Netherlands, Spain, France, Germany, United Kingdom, Luxembourg
Cancer Research Antwerp

Completed

A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates (Destroy)

Metastatic Cancer

Belgium
University Hospital, Ghent

Completed

Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers

Thyroid Cancer

Belgium
Cristal Therapeutics

Completed

A Study of CriPec® Docetaxel Given to Patients With Solid Tumours (NAPOLY)

Cancer | Metastatic Cancer | Solid Tumors

Netherlands, Belgium
Novartis Pharmaceuticals

Terminated

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

Metastatic Cancer With Impaired Renal Function | Metastatic Cancer With Normal Renal Function

Belgium
Brugmann University Hospital

Unknown

Magnetic Resonance Imaging of the Whole Body, Including Diffusion, in the Medical Evaluation of Breast Cancers at High Risk for Metastasis and the Follow-up of Metastatic Cancers

Metastatic Breastcancer

Belgium
Cliniques universitaires Saint-Luc- Université...

Unknown

An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors (NICE-COMBO)

Metastatic Cancer

Belgium
Xenothera SAS

Recruiting

FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23)

Metastatic Cancer | Advanced Solid Tumor

France, Belgium
Genzyme, a Sanofi Company

Active, not recruiting

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment (88)

Medullary Thyroid Cancer | Locally Advanced or Metastatic Medullary Thyroid Cancer

Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Finland, Germany, Greece, India, Israel, Italy, Korea, Republic of, Poland, Russian Federation, Sweden, United Kingdom
The Belgian Society of Medical Oncology

Recruiting

The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment

Metastatic Cancer

Belgium
The Belgian Society of Medical Oncology
Illumina, Inc.; OncoDNA; PierianDx

Recruiting

A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre (BALLETT)

Solid Tumor | Metastatic Cancer

Belgium
University Hospital, Ghent

Completed

Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer

Metastatic Urothelial Cancer

Belgium
The Belgian Society of Medical Oncology
Roche Pharma AG; Foundation Medicine; Sciensano

Recruiting

A Study to Examine the Value of Broad Agnostic Next Generation Sequencing (NGS) Panel Testing Versus Reimbursed Organ-directed NGS: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Center

Metastatic Cancer | Local Tumor Invasion

Belgium
Daiichi Sankyo
AstraZeneca

Recruiting

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Metastatic Cancer | Advanced Cancer

Spain, Korea, Republic of, Belgium, Italy, France, United States, Australia, Japan, Taiwan, United Kingdom
European Organisation for Research and Treatment...

Terminated

Adjuvant Radiation Therapy in Treating Patients With Brain Metastases

Metastatic Cancer

France, Finland, United Kingdom, Belgium, Israel, Germany, Switzerland, Netherlands, Turkey, Italy, Portugal, Spain, Latvia
Universitaire Ziekenhuizen KU Leuven

Recruiting

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer (SPARKLE)

Prostate Cancer | Metastatic Cancer | Prostate Cancer Recurrent | Prostate Cancer Metastatic | Oligometastasis | Oligometastatic Disease | Hormone Sensitive Prostate Cancer

Belgium
Exelixis

Completed

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM)

Thyroid Cancer

France, United Kingdom, United States, Spain, Austria, Israel, Portugal, Saudi Arabia, Netherlands, Greece, Canada, Brazil, Chile, Poland, Italy, Russian Federation, Sweden, Germany, Denmark, India, Switzerland, Belgium, Korea, Republic... and more
Jules Bordet Institute
GlaxoSmithKline; Schering-Plough

Completed

Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer (LAPTEM)

Metastatic Breast Cancer | Brain Metastases | HER2 Positive

Belgium
Hyperfusion
University Hospital, Ghent

Unknown

DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria

Metastatic Lung Cancer | Cancer, Lung | Metastatic Liver Cancer | Cancer Liver | Perfusion Computed Tomography Target Lesion

Belgium
Jules Bordet Institute

Unknown

Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer

Breast Cancer | Metastatic Cancer

Belgium
Amal Therapeutics
Boehringer Ingelheim

Active, not recruiting

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer (KISIMA-01)

Metastatic Colorectal Cancer | Colorectal Cancer | Liver Metastasis Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | MSS

United States, Belgium, Switzerland, Germany
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Metastatic Breast Cancer | Metastatic Triple Negative Breast Cancer

Japan, Belgium, France, Netherlands
University Ghent
University Hospital, Geneva

Active, not recruiting

PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM)

Prostate Cancer | Metastatic Cancer | Prostate Cancer Metastatic | Oligometastatic Cancer

Norway, Spain, Belgium, Switzerland, Australia, Italy
Jules Bordet Institute

Completed

The Jules Bordet Institute Molecular Profiling Program Feasibility Trial (PRECISION-F)

Metastatic Melanoma | Colorectal Cancer Metastatic | Metastatic Non-Small Cell Lung Carcinoma

Belgium
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

Thyroid Cancer

United States, Canada, Germany, Korea, Republic of, Spain, France, Australia, Belgium, Denmark, Israel, Italy, Poland, Romania, Russian Federation, Sweden, United Kingdom
PharmaMar

Completed

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

Metastatic Colorectal Cancer | Pancreatic Cancer | Metastatic Breast Cancer

Spain, Belgium
ABSCINT NV/SA

Not yet recruiting

HER2 Targeted Molecular Imaging in mBC Using 68Ga-ABS011 (HERMIA)

Metastatic Breast Cancer

Belgium
Ipsen

Terminated

Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

Gastric Cancer | Colorectal Cancer | Bone Cancer | Squamous Cell Carcinoma of the Head and Neck | Advanced Cancer | Recurrent Disease | Pancreatic Ductal Adenocarcinoma | Metastatic Tumours

United States, France, Belgium, Switzerland, Netherlands
Stemline Therapeutics, Inc.

Completed

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Metastatic Breast Cancer

Netherlands, Belgium
Eisai Inc.

Completed

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) (SELECT)

Thyroid Cancer

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Denmark, France, Germany, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Russian Federation, Spain, Sweden, Thailand, United Kingdom
Genzyme, a Sanofi Company

Active, not recruiting

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Thyroid Cancer

United States, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, India, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Spain, Sweden, Switz...
University Hospital, Ghent

Recruiting

Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer (DART)

Prostate Cancer | Metastatic Cancer | Prostate Cancer Recurrent | Prostate Cancer Metastatic | Oligometastasis

Belgium
Modra Pharmaceuticals

Completed

ModraDoc006/r in Patients With Breast Cancer

Metastatic Breast Cancer | Recurrent Breast Cancer

Denmark, Belgium, Spain
ElmediX

Recruiting

Safety Study of Whole Body Hyperthermia for Advanced Cancer (MATTERS)

Advanced Cancer | Pancreatic Cancer Metastatic

Belgium
Akamis Bio

Completed

Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients (EVOLVE)

Metastatic Colorectal Cancer | Metastatic Bladder Cancer | Solid Tumours of Epithelial Origin

Belgium, Spain
Jules Bordet Institute

Completed

PET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome. (earlyPETmCRC)

Colorectal Cancer Metastatic | Early Response Evaluation | Fdg-PET

Belgium
University Hospital, Ghent

Recruiting

Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial (LoMP II)

Prostate Cancer Metastatic

Belgium
Celyad Oncology SA

Terminated

Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer (LINK)

Colon Cancer Liver Metastasis

Belgium
Oslo University Hospital
Bristol-Myers Squibb; Helse Stavanger HF; Sorlandet Hospital HF; Cliniques universitaires... and other collaborators

Completed

Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer (ICON)

Breast Cancer | Metastatic Breast Cancer | Hormone Receptor Positive Tumor

Norway, Belgium
University Hospital, Ghent
University Ghent; Kom Op Tegen Kanker

Active, not recruiting

MIDRIX4-LUNG Dendritic Cell Vaccine in Patients With Metastatic Non-small Cell Lung Cancer (MIDRIX4-LUNG)

Non-small Cell Lung Cancer Metastatic

Belgium
Amgen
Roche-Genentech

Completed

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Metastatic Colorectal Cancer | Metastatic Triple Negative Breast Cancer

United States, Belgium, Spain, Australia, Switzerland, Germany
Terumo Europe N.V.
Universitaire Ziekenhuizen KU Leuven; Federation Francophone de Cancerologie...

Completed

LifePearl-Iri Pharmacokinetic Study

Metastatic Colorectal Cancer | mCRC

Belgium, Germany
Aristotle University Of Thessaloniki

Not yet recruiting

Predictive Factors for Medullary Thyroid Cancer Aggressiveness (MYELO)

Medullary Thyroid Cancer

China, Switzerland, Spain, Greece, United States, Austria, Belgium, Brazil, Bulgaria, Colombia, Croatia, France, India, Iraq, Italy, Jordan, Morocco, Poland, Serbia, Slovakia, Thailand, Turkey, Ukraine, Vietnam
Jules Bordet Institute
Breast International Group

Completed

BIG Molecular Screening Feasibility Study (BIG MS Pilot)

Metastatic Breast Cancer

Belgium, Spain, Germany, United Kingdom
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

Medullary Thyroid Cancer

United States, Canada, Spain, China, Australia, Japan, India, Germany, France, Netherlands, Czechia, Brazil, Korea, Republic of, Italy, Israel, Greece, United Kingdom, Belgium, Poland, Russian Federation
EMD Serono

Terminated

MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

Italy, Spain, Belgium

Clinical Trials on Metastatic Differentiated Thyroid Cancer in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations